4D pharma plc (LBPS) News
Filter LBPS News Items
LBPS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest LBPS News From Around the Web
Below are the latest news stories about 4D PHARMA PLC that investors may wish to consider to help them evaluate LBPS as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayThe biggest pre-market stock movers for Thursday are ready and waiting so let's see what's moving the market this morning! |
Analysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX), Baudax Bio (BXRX) and 4d Pharma (LBPS)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Onconova Therapeutics (ONTX – Research Report), Baudax Bio (BXRX – Research Report) and 4d Pharma (LBPS – Research Report) with bullish sentiments. Onconova Therapeutics (ONTX) In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Onconova Therapeutics, with a price target of $11.00. The company's shares closed last Friday at $1.85, close to its 52-week low of $1.38. According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of 5.4% and a 32.9% success rate. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning, investor! |
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022LEEDS, England, March 31, 2022--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial results for the full year ending December 31, 2021 and highlighted its key corporate objectives for 2022. |
Analysts Offer Insights on Healthcare Companies: Star Equity Holdings (STRR) and 4d Pharma (LBPS)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Star Equity Holdings (STRR – Research Report) and 4d Pharma (LBPS – Research Report) with bullish sentiments. Star Equity Holdings (STRR) In a report released yesterday, Tate Sullivan from Maxim Group reiterated a Buy rating on Star Equity Holdings, with a price target of $3.50. The company's shares closed last Wednesday at $1.21, close to its 52-week low of $1.08. According to TipRanks. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayRise and shine, trader! |
4D Pharma Shares Soar On MRx0518/Keytruda Combo Trial Data In Renal Cell Carcinoma4D pharma plc (NASDAQ: LBPS) has announced interim results from Phase 1/2 study evaluating the combination of MRx0518 and Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) for renal cell carcinoma (RCC). The Part B of its signal finding study of MRx0518 & Keytruda combo in solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI) had met its primary efficacy endpoint ahead of enrollment completion. The primary efficacy endpoint for Part B of the study is more than three |
Midday Stock Movers: GameStop, 4D Pharma Rise; Adobe, Vicor SlideBy Sam Boughedda |
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell CarcinomaLEEDS, England, March 23, 2022--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that in Part B of its signal finding study of MRx0518 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met its |